Asia Pacific Lung Cancer Screening Market Forecast to 2030 – Regional Analysis – by Cancer Type [Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer], Technology [Low-Dose Computed Tomography (LDCT), Chest X-Ray, Liquid Biopsy, and Others], Age

Asia Pacific Lung Cancer Screening Market Forecast to 2030 – Regional Analysis – by Cancer Type [Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer], Technology [Low-Dose Computed Tomography (LDCT), Chest X-Ray, Liquid Biopsy, and Others], Age Group (50 & Older and Below 50), and End User (Hospitals, Diagnostic Centers, and Others)

The Asia Pacific lung cancer screening market is expected to grow from US$ 711.20 million in 2022 to US$ 1,362.43 million by 2030. It is estimated to grow at a CAGR of 8.5% from 2022 to 2030.

Structured Lung Cancer Screening Program Fuel Asia Pacific lung Cancer Screening Market

Several countries face challenges with lung cancer screening programs. A few examples of population-based Australian screening programs are BreastScreen, the National Bowel Cancer Screening Program, and the National Cervical Screening Program.

On behalf of the Ministry of Health, the RIVM Center for Population Screening (RIVM-CvB) leads and manages the National Population Screening Programme; under which all Dutch citizens are invited, at a certain point in their lives, to participate in one of the national screening programs. The State begins, sets up, and finances three cancer population screening programs.

Therefore, there is a crucial requirement for a well-structured program such as a community-based program or a shared, informed decision-making program between clinicians and potential participants; accredited reporting centers; and a central data registry for quality control, monitoring, and outcome reporting. Additionally, integrated smoking cessation intervention, international data supporting cost-effectiveness, additional mortality benefits, and a high sustainability rate are a few factors that must be studied for lung cancer screening. Further, the International Association for the Study of Lung Cancer recommends implementing feasibility screening programs in the countries of Asia Pacific without participating in lung cancer screening studies. These programs involve smoking cessation initiatives, standardized algorithms for selecting and managing screening participants, and specialist multidisciplinary teams to manage participants with positive screening results. Therefore, the implementation of structured lung cancer screening programs is expected to be a lucrative opportunity in the lung cancer screening market during the forecast period.

Asia Pacific Lung Cancer Screening Market Overview

The Asia Pacific lung cancer screening market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The regional growth is attributed to various factors, such as the increasing incidence of lung cancer and growing prevalence of cigarette smoking among people. Also, rising government support for screening has led to the further growth of the market.

Asia Pacific lung cancer screening market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Lung Cancer Screening Market Segmentation

The Asia Pacific lung cancer screening market is segmented into cancer type, technology, age group, end user, and country.

Based on cancer type, the Asia Pacific lung cancer screening market is segmented into Non–Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer. The non–small cell lung cancer (NSCLC) segment held a larger share of the Asia Pacific lung cancer screening market in 2022.

Based on technology, the Asia Pacific lung cancer screening market is segmented into chest x-ray, low dose computed tomography (LDCT), liquid biopsy, and others. Chest x-ray segment held the largest share of the Asia Pacific lung cancer screening market in 2022.

Based on age group, the Asia Pacific lung cancer screening market is segmented into 50 and older, and below 50. 50 and older segment held the larger share of the Asia Pacific lung cancer screening market in 2022.

Based on end user, the Asia Pacific lung cancer screening market is segmented into hospital, diagnostic centre, and others. Hospital segment held the largest share of the Asia Pacific lung cancer screening market in 2022.

Based on country, the Asia Pacific Lung Cancer Screening Market is segmented into China Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific lung cancer screening market in 2022.

Intelerad Medical Systems Incorporated, Nuance Communications Inc, GE HealthCare Technologies Inc, Medtronic Plc, Canon Medical Systems Corp, Koninklijke Philips NV, and Siemens AG are some of the leading companies operating in the Asia Pacific lung cancer screening market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific Lung Cancer Screening Market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in Asia Pacific Lung Cancer Screening Market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Asia Pacific Market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.